HF4179

Minnesota Parkinson's Research Trust Fund established, report required, and money appropriated.
Legislative Session 94 (2025-2026)

Related bill: SF4113

AI Generated Summary

4. Purpose and findings

  • Parkinsons disease is a major, ongoing health challenge with significant patient, caregiver, and cost burdens.
  • The bill seeks to accelerate innovation in Parkinsons research and provide support for caregivers, by creating a dedicated funding stream and governance to oversee research and related activities.
  • It aims to attract researchers, strengthen Minnesota’s research status, and foster collaboration among universities, medical centers, and other grant recipients.

4. Establishment of the fund

  • Creates the Minnesota Parkinsons Research Trust Fund in the state treasury as a special revenue fund (not the general fund).
  • Money in the fund is held in trust and may be spent only for the purposes in this section.

4. Purposes

  • Create and speed up innovation in Parkinsons disease and related disorders research.
  • Improve health outcomes for Minnesota residents and increase the chances of medical breakthroughs.
  • Enhance Minnesota’s research standing and attract scientific talent and jobs.
  • Develop and implement a research plan that promotes collaboration among eligible higher education institutions, partners, and other grant recipients.

4. Powers and duties

  • The commissioner of health may award grants to Minnesota-based institutions, research facilities, and other entities involved in Parkinsons research, including translational and clinical research into causes, prevention, treatment, rehabilitation, and therapies.
  • Grants may cover research activities, facilities, equipment, salaries, and related costs; include prevention programs and strategies.
  • The commissioner must collaborate with state agencies and relevant groups to maximize health care and research impact, set standards, oversee grant use, and manage staff, contracts, and compliance.
  • The commissioner shall monitor grant proposals for conflicts of interest and coordinate with a statewide registry for related research.

4. Administration and oversight

  • Establishes a Neurodegenerative Disease Advisory Council to oversee the fund’s administration.
  • Council composition includes leading Minnesota research institutions, Parkinsons advocacy groups, caregiver support groups, and medical professionals specializing in neurological diseases.
  • The council sets guidelines for grant applications, selection criteria, and reporting to ensure transparency and accountability.

4. Reporting and accountability

  • Grant recipients must submit annual reports detailing research progress, caregiver support outcomes, and recommendations to improve programs.
  • The commissioner must produce an annual report by January 31 to legislative chairs and ranking minority members, including:
    • List and amounts of grants awarded, research accomplishments, and progress of grant recipients.
    • Strategic research plans, estimated statewide costs of Parkinsons and related disorders (including Medicaid and retirement systems), and grants compliance program activities.
    • A publication-ready summary on the fund’s grants and impacts.

4. State plan to address neurodegenerative diseases

  • Within 12 months of the act’s effective date, the commissioner (with input from the advisory council and stakeholders) must publish a state plan addressing neurodegenerative diseases.
  • Plan components include: prevalence/incidence data, objectives across prevention, diagnosis, care, research, surveillance, workforce, and support services; strategies for early diagnosis and access to specialists; care coordination and caregiver support; workforce development; public awareness with an equity focus; data/registry integration; a prioritized research and innovation agenda; sustainable financing; evaluation metrics; and a public comment period of at least 30 days before finalization.

4. Coordination of activities

  • The commissioner must coordinate activities with federal agencies, federally supported research centers, academic medical centers, and private partners to leverage resources and avoid duplication.
  • May enter into memoranda of understanding to facilitate data sharing and collaborative research, as permitted by law.

4. Protections and limitations

  • Participation in the data registry is voluntary; no one is denied services for choosing not to enroll.
  • Data collected may only be used for research purposes and not for nonresearch law enforcement or discriminatory uses.
  • The act does not require additional insurance coverage beyond existing state/federal requirements.

4. Rulemaking and severability

  • The commissioner may adopt rules to implement the act.
  • If any part is held invalid, the remainder remains in effect.

Relevant terms section follows.

Relevant Terms - Minnesota Parkinsons Research Trust Fund - special revenue fund - Parksinsons disease - neurodegenerative diseases - translational research - clinical research - research plan - grants / grant administration - investigator grants - caregiver support - Neurodegenerative Disease Advisory Council - data registry / research registry - data sharing / memoranda of understanding - conflicts of interest - reporting requirements - annual report - state plan - prevention, diagnosis, treatment, rehabilitation - workforce development - public comment - transparency / accountability - compliance / oversight - Medicaid / Teacher Retirement System / Employees Retirement System (cost reporting)

Bill text versions

Showing the most recent version. There are  1  total versions. You must be logged in  to view additional bill text versions.

Actions

DateChamberWhereTypeNameCommittee Name
March 12, 2026HouseActionIntroduction and first reading, referred toHealth Finance and Policy
March 16, 2026HouseActionAuthors added
March 26, 2026HouseActionAuthor added
Showing the 5  most recent stages. This bill has 3  stages in total. Log in to view all stages

Citations

You must be logged in  to view citations.

Progress through the legislative process

17%
In Committee

Sponsors

You must be logged in  to view sponsors.

Loading…